OTCBB:RZLT

Rezolute Stock Insider Trading

Healthcare > Biotechnology

Buy RZLT

*Your capital is at risk

$4.58

+0.580 (+14.50%)

At Close: Jun 03, 2026

Rezolute Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.43. In total, the insiders bought 5.17M and sold 50.5K RZLT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.43
● Buy	5.17M shares
● Sell	50.5K shares
97% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 30, 2026 Buy	Common Shares P-Purchase	Evans Daron CFO	C-Suite Officer	10 000 Value: $28.5K
Mar 02, 2026 Sell	Common Shares F-InKind	Roberts Brian Kenneth Chief Medical Officer	Officer	11 439 Value: $34.2K
Mar 02, 2026 Sell	Common Shares F-InKind	Evans Daron CFO	C-Suite Officer	11 438 Value: $34.2K
Mar 02, 2026 Sell	Common Shares F-InKind	Elam Nevan C CEO	CEO / President	27 618 Value: $82.6K
Dec 16, 2025 Buy	Common Shares P-Purchase	Roberts Brian Kenneth Chief Medical Officer	Officer	28 000 Value: $47.6K
Dec 16, 2025 Buy	Common Shares P-Purchase	Hogenhuis Wladimir Director	Director	5 650 Value: $10K
Dec 15, 2025 Buy	Common Shares P-Purchase	Karnawat Sunil Ratilal Chief Commercial Officer	Officer	12 000 Value: $19.4K
Dec 15, 2025 Buy	Common Shares P-Purchase	Karnawat Sunil Ratilal Chief Commercial Officer	Officer	100 Value: $160
Dec 15, 2025 Buy	Common Shares P-Purchase	Elam Nevan C CEO	CEO / President	32 000 Value: $50.9K
Dec 15, 2025 Buy	Common Shares P-Purchase	Evans Daron CFO	C-Suite Officer	2 500 Value: $4K
Dec 15, 2025 Buy	Common Shares P-Purchase	Evans Daron CFO	C-Suite Officer	2 500 Value: $4K
Dec 15, 2025 Buy	Common Shares P-Purchase	Evans Daron CFO	C-Suite Officer	40 000 Value: $70.6K
Nov 19, 2025 Buy	Director Stock Option (Right to Buy) A-Award	Labrucherie Gil M Director	Director	12 000 Value: $121.9K
Nov 19, 2025 Buy	Common Shares A-Award	Labrucherie Gil M Director	Director	21 000 Value: $213.4K
Nov 19, 2025 Buy	Director Stock Option (Right to Buy) A-Award	Fauchet Philippe Director	Director	12 000 Value: $121.9K
Nov 19, 2025 Buy	Common Shares A-Award	Fauchet Philippe Director	Director	21 000 Value: $213.4K
Nov 19, 2025 Buy	Common Shares A-Award	Karnawat Sunil Ratilal Chief Commercial Officer	Officer	32 000 Value: $325.1K
Nov 19, 2025 Buy	Common Shares A-Award	Roberts Brian Kenneth Chief Medical Officer	Officer	123 000 Value: $1.25M
Nov 19, 2025 Buy	Employee Stock Option (Right to Buy)	Roberts Brian Kenneth Chief Medical Officer	Officer	72 000 Value: $731.5K
Nov 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Karnawat Sunil Ratilal Chief Commercial Officer	Officer	19 000 Value: $193.0K
Nov 19, 2025 Buy	Common Shares A-Award	Elam Nevan C CEO	CEO / President	317 000 Value: $3.22M
Nov 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Elam Nevan C CEO	CEO / President	186 000 Value: $1.89M
Nov 19, 2025 Buy	Common Shares A-Award	Evans Daron CFO	C-Suite Officer	107 000 Value: $1.09M
Nov 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Evans Daron CFO	C-Suite Officer	63 000 Value: $640.1K
Nov 19, 2025 Buy	Common Shares A-Award	Kreher Nerissa Director	Director	21 000 Value: $213.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT REZOLUTE, INC.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrei...

Read Full Profile Here